The ultrastructural evidence of membrane perforation and morphological collapse deserves careful interpretation in light of the flow cytometry data. Annexin V staining detects the externalization of phosphatidylserine, an event classically associated with apoptosis but also reproducible in necrotic death when membrane integrity fails, while propidium iodide entry marks loss of plasma membrane barrier function. The observation that the Annexin V-positive and propidium iodide-positive population rose together in a dose-dependent fashion is therefore compatible with cells progressing from early apoptotic signaling into late apoptosis with secondary membrane rupture, but it is equally compatible with primary necrotic lysis in which phosphatidylserine flips to the outer leaflet as an epiphenomenon of membrane disorganization. The authors of the study appropriately acknowledged this ambiguity, and it remains one of the central unresolved questions in melittin pharmacology: whether the peptide kills tumor cells primarily by punching pores in their membranes or whether sublytic concentrations first trigger organized apoptotic programs that only later culminate in membrane failure. Distinguishing between these possibilities would require time-resolved assays of caspase activation, mitochondrial membrane potential, and cytochrome c release performed at concentrations below the lytic threshold, and such experiments would materially inform whether melittin or its derivatives could be developed as pro-apoptotic therapeutics rather than as nonspecific membrane-disrupting agents.

The transcriptomic dimension of the study adds a layer of molecular context that phenotypic assays alone cannot supply. By profiling gene expression after melittin treatment, the investigators were able to observe not merely that cells died but which cellular systems collapsed first and most dramatically. The finding that ribosomal biogenesis genes were globally suppressed is noteworthy because ribosome production is among the most energy-intensive processes in proliferating cells, and its suppression is a recognized hallmark of nucleolar stress. When ribosomal assembly is disrupted, the nucleolus releases factors that stabilize p53 and initiate cell cycle arrest or apoptosis, and although the U14 line used here is a murine model whose p53 status would need to be verified, the transcriptional signature of ribosomal shutdown is consistent with a cell that has lost the capacity to sustain protein synthesis. Similarly, the coordinated downregulation of mitochondrial oxidative phosphorylation genes suggests that melittin treatment deprived cells of their primary ATP-generating machinery, which would compound the energetic cost of attempting to repair a perforated plasma membrane. The coupling of these two metabolic catastrophes, impaired protein synthesis and impaired respiration, creates a situation from which recovery is essentially impossible, and this may explain why even brief exposures produced durable losses of colony-forming ability in the seven-day clonogenic assay.

The downregulation of Etv2, a transcription factor best known for its role in specifying endothelial and vascular lineages during embryonic development, opens an intriguing line of speculation regarding melittin’s possible effects on the tumor microenvironment. Cervical tumors, like most solid malignancies, depend on angiogenesis for sustained growth beyond a few cubic millimeters, and transcriptional programs that suppress vascular development genes within tumor cells could theoretically impair paracrine signaling to endothelial cells or reduce the tumor’s capacity to support vascular mimicry. It must be emphasized that a single-cell-line transcriptomic experiment cannot establish an anti-angiogenic effect in vivo, and the connection between Etv2 suppression in U14 cells and any measurable change in blood vessel formation remains hypothetical. Nevertheless, the observation is consistent with earlier reports that melittin-containing preparations, including purified peptide and bee venom itself, can inhibit angiogenesis in experimental models, and it suggests a mechanism by which melittin might exert indirect antitumor effects beyond direct cytotoxicity.

The pronounced upregulation of Jun, Fos, and Fosb points to activation of the AP-1 transcriptional complex, a collection of dimeric transcription factors assembled from Jun and Fos family members that coordinate cellular responses to stress, proliferation signals, and differentiation cues. AP-1 activation in the context of melittin treatment is most plausibly interpreted as a stress response, since membrane damage, oxidative stress, and metabolic collapse are all canonical triggers of JNK and p38 mitogen-activated protein kinase signaling, which converge on AP-1. However, AP-1 is a context-dependent regulator whose effects range from promoting apoptosis to driving proliferation and invasion depending on the composition of the dimer, the duration of activation, and the cooperating transcription factors available in a given cell type. The sustained or excessive activation of AP-1 in a cell already committed to death may simply be a transcriptional echo of the stress response rather than a causal driver of the phenotype, and disentangling cause from consequence would require perturbation experiments in which AP-1 activity is pharmacologically or genetically inhibited prior to melittin exposure.

Several methodological considerations frame the interpretation of these findings. The U14 cell line is a murine cervical cancer model originally derived from carcinogen-induced tumors in mice, and while it has been used extensively in preclinical cervical cancer research, its genomic and transcriptomic characteristics differ in important respects from human HPV-positive cervical carcinomas, which are driven by the E6 and E7 oncoproteins of high-risk papillomavirus types. The authors noted that prior work has shown melittin can downregulate HPV E6 and E7 expression, which would be a mechanism of particular relevance to human disease but which cannot be directly assessed in a murine line lacking those viral oncogenes. Translating the present findings into a human context will therefore require validation in HPV-positive cell lines such as HeLa, SiHa, or CaSki, and ultimately in organoid models or patient-derived xenografts that preserve the genomic heterogeneity of clinical tumors.

The reuse of a previously generated transcriptomic dataset, combined with newly acquired phenotypic data, is an efficient research strategy but also introduces the possibility that the RNA sequencing and the viability, migration, and ultrastructure assays were not performed under strictly identical conditions. Differences in passage number, confluence, serum conditions, or timing between the original sequencing experiment and the new phenotypic work could introduce batch effects that complicate the integration of transcriptional and phenotypic observations. The selection of four micrograms per milliliter as the intervention concentration was justified by the dose-response data, but transcriptomic profiles at a single concentration capture a snapshot of one point in a dynamic process, and earlier or later time points might reveal additional regulatory programs, such as inflammatory signaling, immune-related gene induction, or DNA damage response pathways, that are not visible at the chosen sampling time.

From a therapeutic development standpoint, the central obstacle to melittin’s clinical use has always been its nonspecific lytic activity against normal cells, particularly erythrocytes, which express sufficient anionic surface charge to bind the peptide and undergo hemolysis at concentrations not far above those needed to kill tumor cells in vitro. Various strategies have been explored to narrow this therapeutic window, including conjugating melittin to tumor-targeting antibodies or nanoparticles, engineering the peptide to remain inactive in circulation and activate only in the tumor microenvironment, and synthesizing analogues with reduced hemolytic potency but retained cytotoxicity toward malignant cells. The transcriptomic framework described in this study could assist such efforts by identifying downstream molecular markers, such as ribosomal stress signatures or AP-1 activation patterns, that could serve as pharmacodynamic biomarkers to confirm target engagement in future preclinical and clinical studies without relying solely on membrane damage as a readout.

The public health context motivating this research is substantial. Cervical cancer remains a leading cause of cancer mortality among women in low- and middle-income countries, where screening coverage is limited and access to HPV vaccination is uneven. Even in settings with robust vaccination programs, a generation will pass before herd immunity substantially reduces incidence among women already exposed to the virus, and therapeutic options for recurrent or metastatic disease remain limited, with immune checkpoint inhibitors benefiting only a minority of patients at considerable cost. Natural products and their derivatives have historically been a productive source of anticancer drugs, and venom-derived peptides represent a largely untapped chemical space with mechanisms of action distinct from those of conventional cytotoxic agents. The present study contributes to this field by providing a systematic, if preliminary, molecular map of how melittin perturbs cervical cancer cells, linking physical membrane disruption to metabolic collapse and specific transcriptional responses, and thereby offering a foundation upon which more targeted and less toxic melittin-based therapeutics might eventually be designed.

Future work building on these findings would benefit from several extensions. Dose-response and time-course transcriptomic experiments could delineate the temporal sequence of molecular events, distinguishing primary effects of membrane interaction from secondary consequences of metabolic failure. Proteomic and metabolomic profiling would complement the RNA-level view by revealing changes in protein abundance and metabolic flux that transcriptomics alone cannot capture. In vivo studies in immunocompetent mouse models of cervical cancer would be essential to determine whether the anti-angiogenic and cytotoxic effects observed in vitro translate into tumor regression, and whether the immune system contributes to or modulates melittin’s antitumor activity in a living organism. Finally, comparative studies across a panel of cervical cancer cell lines with differing HPV status, p53 function, and drug resistance profiles would clarify which molecular contexts predict sensitivity to melittin, moving the field toward the kind of biomarker-driven patient selection that has transformed the clinical utility of other targeted agents.

Subject of Research: cervical cancer

Article Title: Exploratory transcriptomic profiling of melittin’s efficacy in the treatment of murine cervical cancer cells

Article References: Jiang, J., Zhang, Y., Wang, M., Zhang, R., Li, Y., Qiu, J., Chen, D., Yan, T., Guo, R., & Liu, Y. (2026). Exploratory transcriptomic profiling of melittin’s efficacy in the treatment of murine cervical cancer cells. Frontiers in Cell and Developmental Biology, 14, Article 1975665. https://doi.org/10.3389/fcell.2026.1975665

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1975665

Keywords: melittin, cervical cancer, bee venom, transcriptomics, AP-1, cancer biology, Exploratory, transcriptomic, profiling, efficacy, treatment, murine

The concept of an adjuvant is not new. Adjuvants are agents administered alongside antigens to boost the quality, magnitude or duration of an immune response. Aluminum-based salts have dominated vaccine formulation for nearly a century, and the field’s origins trace back even further, to William B. Coley’s late nineteenth-century experiments with bacterial toxins to treat sarcomas. What has changed is the sophistication with which scientists can now dissect how adjuvants work at the molecular level. Modern immunology has revealed that effective adjuvants do far more than simply irritate the immune system into action. They promote the activation and maturation of antigen-presenting cells, the dendritic cells and macrophages that patrol tissues and sample their surroundings for danger. Once activated, these cells process tumor or vaccine antigens and display fragments of them on major histocompatibility complex molecules, the molecular billboards that cytotoxic T lymphocytes must read before they can kill a target cell.

This is precisely where natural adjuvants show their strength, according to the review. Compounds extracted from plants, microorganisms and animals can stimulate the signaling pathways that govern cytokine production and T-cell activation, effectively converting a weak or tolerogenic encounter with a tumor antigen into a robust, cell-killing immune response. The authors emphasize that natural products offer remarkable structural diversity and a broad repertoire of biological activities, qualities that synthetic chemists have long tried to emulate. Yet the review is equally candid about the caveats: chemical inertness, batch-to-batch variability, and safety must be rigorously evaluated and standardized before these compounds can be deployed in the clinic. Evidence quality also varies considerably across cancer types and experimental systems, a point the authors stress rather than gloss over.

Among the plant-derived candidates, few have attracted as much sustained attention as neem leaf glycoprotein, a compound with an unusually well-documented immunological dossier. Studies spanning nearly two decades have shown that neem leaf glycoprotein can drive carcinoembryonic antigen-specific anti-tumor immune responses by harnessing macrophage-mediated antigen presentation. More recent work has illuminated the mechanism in striking detail: the glycoprotein binds to Dectin-1 receptors on dendritic cells, triggering a CARD9-mediated intracellular signaling cascade that activates the transcription factor NF-kappaB and skews the immune system toward a type-1, cell-mediated response, the arm of immunity most effective against tumors. Additional preclinical studies suggest the glycoprotein can counterbalance the immunosuppressive effects of tumor-associated mesenchymal stem cells, restore exhausted CD8-positive T-cell function against cancer stem cells, and even delay chemically induced oral carcinogenesis in mouse models.

Polysaccharides form another major pillar of the natural adjuvant repertoire. Beta-glucans, long chains of glucose found in fungal cell walls, have emerged as agonists of Toll-like receptors and inducers of macrophage anti-cancer activity, with recent work on polysaccharides from the mushroom Inonotus obliquus, better known as chaga, demonstrating this receptor-level engagement directly. Plant polysaccharides, meanwhile, are being explored for their ability to reprogram macrophage polarization, shifting tumor-associated macrophages from a pro-tumor, M2-like state toward an anti-tumor, M1-like phenotype. Because tumor-associated macrophages often constitute a large fraction of the tumor mass and actively promote chemoresistance and metastasis, agents capable of flipping their allegiance represent a strategically important class of immunomodulators. Polysaccharides such as those from Angelica sinensis have even been encapsulated into PLGA nanoparticles, demonstrating how ancient remedies can be repackaged with cutting-edge delivery technology to serve as combined vaccine adjuvant and antigen-delivery systems.

The microbial world contributes its own arsenal. Bacterial flagellin, the protein that builds the whip-like appendages of motile bacteria, is a potent agonist of Toll-like receptor 5 and has been engineered into Salmonella typhimurium strains that secrete the molecule to enhance cancer immunotherapy in two-step treatment regimens. Structural biologists are now mapping the minimal domains of flagellin required for TLR5 activation, seeking to strip away immunodominant regions that could provoke unwanted responses while preserving the adjuvant signal, a process known as deimmunization that is considered essential for clinical translation. Bacterial ghosts, the empty cell envelopes of lysed bacteria, and virosomes, engineered virus-like particles, round out the microbial toolkit as delivery platforms that combine antigen carriage with built-in immune stimulation.

Animal-derived compounds add yet another dimension. Bee venom and its principal component melittin have shown the ability to synergize with conventional drugs such as sorafenib against hepatocellular carcinoma cells, and melittin-incorporated nanomedicines are now being developed to harness its cytolytic power while taming its toxicity for enhanced cancer immunotherapy. Silk sericin, the protein that glues silk fibers together, is being investigated as a sustainable biomaterial with immunoregulatory effects on inflammatory pathways, while chitosan, derived from crustacean shells, and its quaternized derivative trimethyl chitosan have established track records as mucosal vaccine adjuvants and nanoparticulate delivery carriers. Saponins, both natural and synthetic, occupy a special place in the adjuvant pantheon, with molecules such as tomatine from tomatoes contributing to the growing family of carbohydrate-based immune stimulants whose mechanisms of action are increasingly well understood.

What unites these disparate compounds is their potential role in cancer vaccines and combination regimens. Depending on formulation, natural adjuvants can serve as components of drug or antigen-delivery systems, be incorporated directly into vaccine production, or act as adjuncts that sensitize tumors to checkpoint inhibitors targeting the PD-1/PD-L1 axis. The review highlights applications across breast cancer, melanoma, liver cancer and prostate cancer, while noting honestly that the strength of supporting evidence differs among these indications. The convergence with nanotechnology is particularly striking: lipid nano drug delivery systems based on traditional Chinese medicine, plant-derived immunomodulatory nanoadjuvants, and beta-glucan-based immunocyte-targeting vehicles all illustrate how natural compounds are being engineered into precisely controlled formulations that can ferry antigens to dendritic cells while simultaneously providing the danger signals those cells need to mount a response.

Challenges remain formidable. The review’s authors are careful to note that natural products can suffer from chemical complexity that complicates standardization, potential toxicity that must be quantified, and mechanisms of action that are sometimes only partially understood, as is the case for the polysaccharide adjuvant inulin, whose mode of action remains elusive despite demonstrated efficacy. Regulatory pathways designed for single, well-defined molecules must adapt to multi-component natural extracts. Clinical evidence, while growing, still lags behind the preclinical enthusiasm, and the historical record of cancer immunotherapy is littered with approaches that worked brilliantly in mice but faltered in humans. The randomized phase III MIND-DC trial of dendritic cell therapy in melanoma, cited in the review, exemplifies both the promise and the difficulty of translating immunological theory into survival benefit.

Nevertheless, the trajectory of the field is unmistakable. From Coley’s crude bacterial toxins to Dectin-1 agonists engineered at the level of individual signaling domains, natural adjuvants have evolved from folk remedies into rationally designed components of sophisticated immunotherapeutic platforms. The SRM Institute team’s synthesis makes a compelling case that plants, fungi, bacteria and animals have already solved, through billions of years of evolution, many of the problems that immunologists are now trying to crack in the laboratory. If the issues of standardization, safety evaluation and clinical validation can be resolved, natural adjuvants may well become indispensable partners to the checkpoint inhibitors, therapeutic vaccines and nanomedicines that define contemporary cancer treatment, offering patients the prospect of powerful anti-tumor immunity with fewer of the harsh side effects that have long been the price of fighting cancer.

Subject of Research: Natural product-derived immune adjuvants for cancer immunotherapy

Article Title: Empowering cancer therapy: the promise of natural adjuvants

Article References: De, T., Bibi, R., & Sarkar, K. (2026). Empowering cancer therapy: the promise of natural adjuvants. Molecular Biology Reports, 53(1), Article 1627. https://doi.org/10.1007/s11033-026-12800-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12800-z

Keywords: cancer immunotherapy, natural adjuvants, neem leaf glycoprotein, antigen-presenting cells, polysaccharides, beta-glucan, melittin, chitosan, Toll-like receptors, dendritic cells, cancer vaccines, tumor microenvironment